Astrazeneca Pharma India Ltd launched an antiplatelet drug Brilinta (Ticagrelor) on 18 October 2012 in India. Brilinta that is an oral antiplatelet treatment of adult patients is used for treating acute coronary syndromes.
The drug has a property of preventing formation of new clots in the blood and eases its flow within the body. This helps in reducing the risks of cardiovascular attack like cardiovascular death and heart attacks. The drug got its approval for marketing the tablets by the name of Brilinta (Ticagrelor) by the Drug Controller General of India following the recommendations made by New Drug Advisory Committee in May 2012.
Antiplatelet Drug Brilinta launched by Astrazeneca Pharma
Subscribe to:
Post Comments (Atom)
LinkWithin
No comments:
Post a Comment